| __timestamp | Mesoblast Limited | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 17986000 |
| Thursday, January 1, 2015 | 65378000 | 32480000 |
| Friday, January 1, 2016 | 52263000 | 68081000 |
| Sunday, January 1, 2017 | 35072000 | 169906000 |
| Monday, January 1, 2018 | 27415000 | 248932000 |
| Tuesday, January 1, 2019 | 36983000 | 354100000 |
| Wednesday, January 1, 2020 | 50918000 | 433300000 |
| Friday, January 1, 2021 | 63586000 | 583300000 |
| Saturday, January 1, 2022 | 57967000 | 752700000 |
| Sunday, January 1, 2023 | 53107000 | 887600000 |
| Monday, January 1, 2024 | 23626000 | 1007200000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Neurocrine Biosciences, Inc. and Mesoblast Limited have demonstrated contrasting SG&A spending patterns. From 2014 to 2023, Neurocrine Biosciences saw a staggering increase of nearly 4,800% in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Mesoblast Limited's SG&A expenses have remained relatively stable, with a modest 2% decrease over the same period, indicating a more conservative approach. Notably, 2024 data for Neurocrine is missing, leaving room for speculation on their future strategy. These spending patterns highlight the diverse strategies employed by biotech firms to navigate the industry's challenges and opportunities.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Breaking Down SG&A Expenses: Veracyte, Inc. vs Mesoblast Limited
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?
Mesoblast Limited and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared